Targeting the A₃ adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

References

• KroschinskyFStölzelFvon BoninSIntensive Care in Hematological and Oncological Patients (iCHOP) Collaborative GroupNew drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their managementCrit Care20172118928407743
   PubMed Web of Science ®Google Scholar
• WeiGHuYPuCCD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled studyAnn Hematol201897578178929417201
   PubMed Web of Science ®Google Scholar
• KochenderferJNRosenbergSATreating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptorsNat Rev Clin Oncol201310526727623546520
   PubMed Web of Science ®Google Scholar
• RestifoNPDudleyMERosenbergSAAdoptive immunotherapy for cancer: harnessing the T cell responseNat Rev Immunol201212426928122437939
   PubMed Web of Science ®Google Scholar
• SharmaPWagnerKWolchokJDAllisonJPNovel cancer immunotherapy agents with survival benefit: recent successes and next stepsNat Rev Cancer2011111180581222020206
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature2011480737848048922193102
   PubMed Web of Science ®Google Scholar
• WangMYinBWangHYWangRFCurrent advances in T-cell-based cancer immunotherapyImmunotherapy20146121265127825524383
   PubMed Web of Science ®Google Scholar
• LeeDWGardnerRPorterDLCurrent concepts in the diagnosis and management of cytokine release syndromeBlood2014124218819524876563
   PubMed Web of Science ®Google Scholar
• NCI-CTC, common terminology criteria for adverse events (CTCAE) v4.02010 Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmAccessed January 21, 2019
   Google Scholar
• MaudeSLBarrettDTeacheyDTGruppSAManaging cytokine release syndrome associated with novel T cell-engaging therapiesCancer J201420211912224667956
   PubMed Web of Science ®Google Scholar
• TurtleCJHanafiLABergerCCD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsJ Clin Invest201612662123213827111235
   PubMed Web of Science ®Google Scholar
• ParkJHRivièreIGonenMLong-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemiaN Engl J Med2018378544945929385376
   PubMed Web of Science ®Google Scholar
• MaudeSLLaetschTWBuechnerJTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemiaN Engl J Med2018378543944829385370
   PubMed Web of Science ®Google Scholar
• XuXJTangYMCytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cellsCancer Lett2014343217217824141191
   PubMed Web of Science ®Google Scholar
• MaudeSLFreyNShawPAChimeric antigen receptor T cells for sustained remissions in leukemiaN Engl J Med2014371161507151725317870
   PubMed Web of Science ®Google Scholar
• ColvinGABerzDRamanathanMNon-engraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerismBiol Blood Marrow Transplant200915442143119285629
   PubMed Web of Science ®Google Scholar
• MiharaMHashizumeMYoshidaHSuzukiMShiinaMIL-6/IL-6 receptor system and its role in physiological and pathological conditionsClin Sci (Lond)2012122414315922029668
   PubMed Web of Science ®Google Scholar
• NorelliMCamisaBBarbieraGMonocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cellsNat Med201824673974829808007
   PubMed Web of Science ®Google Scholar
• BradleyJRTNF-mediated inflammatory diseaseJ Pathol2008214214916018161752
   PubMed Web of Science ®Google Scholar
• BugelskiPJAchuthanandamRCapocasaleRJTreacyGBouman-ThioEMonoclonal antibody-induced cytokine-release syndromeExpert Rev Clin Immunol20095549952120477639
   PubMed Web of Science ®Google Scholar
• OppertMSchindlerRHusungCLow-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shockCrit Care Med200533112457246416276166
   PubMed Web of Science ®Google Scholar
• DavilaMLRiviereIWangXEfficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaSci Transl Med20146224224ra25
   PubMed Web of Science ®Google Scholar
• NavarroGTaroumianSBarrosoNDuanLFurstDTocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrumsSemin Arthritis Rheum201443445846924262929
   PubMed Web of Science ®Google Scholar
• YokotaSMiyamaeTImagawaTTherapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritisArthritis Rheum200552381882515751095
   PubMed Web of Science ®Google Scholar
• ImagawaTYokotaSMoriMSafety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticularcourse juvenile idiopathic arthritisMod Rheumatol201222110911521667343
   PubMed Web of Science ®Google Scholar
• WangZHanWBiomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapyBiomark Res20182264
   Web of Science ®Google Scholar
• AbbracchioMPP1 and P2 receptors in cell growth and differentiationDrug Dev Res1996393–4393406
   Web of Science ®Google Scholar
• OhanaGBar-YehudaSBarerFFishmanPDifferential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptorJ Cell Physiol20011861192311147810
   PubMed Web of Science ®Google Scholar
• BoreaPAGessiSMerighiSVincenziFVaraniKPharmacology of adenosine receptors: the state of the artPhysiol Rev20189831591162529848236
   PubMed Web of Science ®Google Scholar
• AntonioliLFornaiMBlandizziCPacherPHaskóGAdenosine signaling and the immune system: when a lot could be too muchImmunol Lett Epub2018424
   PubMed Web of Science ®Google Scholar
• DonatoMGelpiRJAdenosine and cardioprotection during reperfusion-an overviewMol Cell Biochem20032511–215315914575317
   PubMed Web of Science ®Google Scholar
• DunwiddieTVMasinoSAThe role and regulation of adenosine in the central nervous systemAnnu Rev Neurosci200124315511283304
   PubMed Web of Science ®Google Scholar
• FishmanPBar-YehudaSFarbsteinTBarerFOhanaGAdenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptorsJ Cell Physiol2000183339339810797314
   PubMed Web of Science ®Google Scholar
• BoreaPAGessiSMerighiSVaraniKAdenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects?Trends Pharmacol Sci201637641943426944097
   PubMed Web of Science ®Google Scholar
• FishmanPBar-YehudaSLiangBTJacobsonKAPharmacological and therapeutic effects of A3 adenosine receptor agonistsDrug Discov Today2012177–835936622033198
   PubMed Web of Science ®Google Scholar
• Bar-YehudaSStemmerSMMadiLThe A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kB signal transduction pathwaysInt J Oncol20083328729518636149
   PubMed Web of Science ®Google Scholar
• GessiSCattabrigaEAvitabileAElevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cellsClin Cancer Res200410175895590115355922
   PubMed Web of Science ®Google Scholar
• MadiLOchaionARath-WolfsonLThe A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibitionClin Cancer Res200410134472447915240539
   PubMed Web of Science ®Google Scholar
• CronsteinBNLow-dose methotrexate: a mainstay in the treatment of rheumatoid arthritisPharmacol Rev200557216317215914465
   PubMed Web of Science ®Google Scholar
• CutoloMSulliAPizzorniCSerioloBStraubRHAnti-inflammatory mechanisms of methotrexate in rheumatoid arthritisAnn Rheum Dis200160872973511454634
   PubMed Web of Science ®Google Scholar
• KimSHNamEJKimYKYeYMParkHSFunctional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin-induced urticariaBr J Dermatol2010163597798520716228
   PubMed Web of Science ®Google Scholar
• VincenziFTargaMCorciuloCPulsed electromagnetic fields increased the anti-inflammatory effect of A2A and A3 adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblastsPLoS One201385e6556123741498
   PubMed Web of Science ®Google Scholar
• AntonioliLFornaiMColucciRThe blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptorsJ Pharmacol Exp Ther2010335243444220668053
   PubMed Web of Science ®Google Scholar
• BaharavEDubrosinAFishmanPBar-YehudaSHalprenMWeinbergerASuppression of experimental zymosan-induced arthritis by intraperitoneal administration of adenosineDrug Dev Res2002574182186
   Web of Science ®Google Scholar
• VaraniKPadovanMVincenziFA2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase releaseArthritis Res Ther2011136R19722146575
   PubMed Web of Science ®Google Scholar
• LawrenceTThe nuclear factor NF-kappaB pathway in inflammationCold Spring Harb Perspect Biol200916a00165120457564
   PubMed Web of Science ®Google Scholar
• OchaionABar-YehudaSCohenSThe anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s diseaseCell Immunol2009258211512219426966
   PubMed Web of Science ®Google Scholar
• CohenSStemmerSMZozulyaGCF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liverJ Cell Physiol201122692438244721660967
   PubMed Web of Science ®Google Scholar
• Bar-YehudaSRath-WolfsonLDel ValleLInduction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatmentArthritis Rheum200960103061307119790055
   PubMed Web of Science ®Google Scholar
• OchaionABar-YehudaSCohenSThe A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis ratsBiochem Pharmacol200876448249418602896
   PubMed Web of Science ®Google Scholar
• CohenSBarerFItzhakISilvermanMHFishmanPInhibition of IL-17 and IL-23 in human keratinocytes by the A3 adenosine receptor agonist PiclidenosonJ Immunol Res2018231097029862305
   PubMed Web of Science ®Google Scholar
• LeeHSChungHJLeeHWJeongLSLeeSKSuppression of inflammation response by a novel A3 adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signalingImmunobiology20112169997100321514967
   PubMed Web of Science ®Google Scholar
• LeeJYJhunBSOhYTActivation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cellsNeurosci Lett200639611616324785
   PubMed Web of Science ®Google Scholar
• HaskóGNémethZHViziESSalzmanALSzabóCAn agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic miceEur J Pharmacol199835832612689822893
   PubMed Web of Science ®Google Scholar
• MableyJSorianoFPacherPThe adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitisEur J Pharmacol2003466332332912694816
   PubMed Web of Science ®Google Scholar
• WagnerRNgamsriKCStarkSVollmerIReutershanJAdenosine receptor A3 is a critical mediator in LPS-induced pulmonary inflammationAm J Physiol Lung Cell Mol Physiol20102994L502L51220639349
   PubMed Web of Science ®Google Scholar
• FishmanPBar-YehudaSMadiLThe PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritisArthritis Res Ther200681R3316507132
   PubMed Web of Science ®Google Scholar
• Bar-YehudaSLugerDOchaionAInhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101Int J Mol Med201128572773121887476
   PubMed Web of Science ®Google Scholar
• TerayamaRTabataMMaruhamaKIidaSA3 adenosine receptor agonist attenuates neuropathic pain by suppressing activation of microglia and convergence of nociceptive inputs in the spinal dorsal hornExp Brain Res20182361232033213
   PubMed Web of Science ®Google Scholar
• LibermannTABaltimoreDActivation of interleukin-6 gene expression through the NF-kappa B transcription factorMol Cell Biol1990105232723342183031
   PubMed Web of Science ®Google Scholar
• MadiLCohnSOchaionAABar-YehudaSBarerFFishmanPOver-expression of A3 adenosine receptor in PBMNC of rheumatoid arthritis patients: involvement of NF-kB in mediating receptor levelJ Rheumatol200734202617216675
   PubMed Web of Science ®Google Scholar
• YuJWangWHuangHEfficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: a systemic review and meta-analysisHematology201924119920730479190
   PubMed Web of Science ®Google Scholar
• LeRQLiLYuanWFDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndromeOncologist201823894394729622697
   PubMed Web of Science ®Google Scholar
• ToniniGSantiniDVincenziBOxaliplatin may induce cytokine-release syndrome in colorectal cancer patientsJ Biol Regul Homeost Agents200216210510912144121
   PubMed Web of Science ®Google Scholar
• GessiSVaraniKMerighiSExpression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activationMol Pharmacol200465371171914978250
   PubMed Web of Science ®Google Scholar
• van TroostenburgARClarkEVCareyWDTolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young menInt J Clin Pharmacol Ther2004421053454215516022
   PubMed Web of Science ®Google Scholar
• SilvermanMHStrandVMarkovitsDClinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trialJ Rheumatol2008351414818050382
   PubMed Web of Science ®Google Scholar
• StemmerSMBenjaminovOMedaliaGCF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation studyOncologist2013181252623299770
   PubMed Web of Science ®Google Scholar
• Shimabukuro-VornhagenAGödelPSubkleweMCytokine release syndromeJ Immunother Cancer2018615629907163
   PubMed Web of Science ®Google Scholar